Evaluation of clinical effect of compound Shelong Capsule on urinary protein in membranous nephropathy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200006490

Enrollment

Unknown

Registered

2022-08-15

Start date

2022-08-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic membranous nephropathy

Interventions

The treatment group:Compound Snake Dragon capsule

The control group:Tripterygium wilfordii polyglycoside tablet

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Consistent with the clinical diagnosis of chronic nephritis and stage I-II pathological diagnosis of membranous nephropathy; (2) TCM syndrome differentiation belongs to the syndrome of mutual obstruction of dampness and stasis; (3)0.3g/24h= 24h urinary protein quantification <3.5g/24h; (4) Serum creatinine =176µmol/L, or glomerular filtration rate (GFR)= 60mL /(min·1.73m2); (5) Aged between 16 and 65, regardless of gender; (6) Acute aggravating factors such as infection, electrolyte disturbance, severe hypertension, hyperlipemia and hyperglycemia can be effectively controlled; (7) Those who voluntarily participate in the experiment and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with serious primary diseases of the heart, brain, liver and hematopoietic system, type 1 diabetes, or other serious diseases affecting their survival; (2) 24-hour urine protein quantification =3.5g/24h or < 0.4g/24h; (3) serum creatinine =177µmol/L, or serum creatinine clearance (GFR)<60ml/(min·1.73m2); (4) pregnant or lactating women; (5) Persons with allergic constitution who have a history of drug allergy or are known to be allergic to the drug components in the test; (6) Those who are taking similar study drugs or antihypertensive drugs with protein-lowering effect or are currently taking hormone or immunosuppressive therapy; (7) mentally ill or legally disabled persons; (8) Those who have no fixed place to work and are easy to fall off; (9) Participants in another clinical drug trial.

Design outcomes

Primary

Measure	Time frame
Total plasma protein;24 hours urinary protein excretio;Serum creatinine;plasma albumin;	—

Secondary

Measure	Time frame
Urine analysis;Urea nitrogen;Total cholesterol;triglycerides;	—

Countries

china

Contacts

Public ContactXing jian yue

13513644593@163.com13513644593

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026